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Abstract
Our aim was to develop and validate the Spanish version of the Amyotrophic Lateral Sclerosis Cognitive Behavioural
Screen (ALS-CBS) and investigate behavioural/cognitive impairment in our ALS patients. We enrolled 50 patients with
definite or probable ALS, evaluated by the Motor Neuron Disease Unit (using El Escorial criteria) and Dementia Unit, and
assessed with the Spanish ALS-CBS. The patients’ cognitive/behavioural status was classified according to current criteria.
Patients were classified into each diagnostic category: ALS-no impairment, 36%; ALS-mild cognitive impairment, 34%;
ALS-mild behavioural impairment, 6%; ALS-mild cognitive/behavioural impairment, 12%; ALS-frontotemporal demen-
tia, 12%. Cognitive impairment was more common in bulbar (90.9%) than spinal (48.7%) forms (p50.012). The Spanish
ALS-CBS was validated. Performance to differentiate normal vs. impaired individuals was: 1) cognition (cut-off 15; AUC,
84.7%): sensitivity 86.2%, specificity 62%, positive predictive value 75.8%, negative predictive value 76.5%; 2) behaviour
(cut-off 36; AUC, 83.3%): sensitivity 93.3%, specificity 74.3%, positive predictive value 61%, negative predictive value
96.3%. Performance to differentiate between patients with and without dementia: 1) cognition (cut-off 8; AUC, 87.3%):
sensitivity 83.3%, specificity 75%, positive predictive value 31.3%, negative predictive value 97.1%; 2) behaviour (cut-off
35; AUC, 80.9%): sensitivity 83.3%, specificity 69%, positive predictive value 25%, negative predictive value 96.7%. In
conclusion, cognitive impairment is common in ALS patients, particularly in bulbar forms. The Spanish version of the
ALS-CBS is useful for screening cognitive/behavioural impairment in this population.
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Introduction
Amyotrophic lateral sclerosis (ALS) was formerly
considered a disease mainly affecting the motor
system, with denial bias regarding cognitive and
behavioural symptoms. Motor symptoms and their
impact on the patients’ daily life have further
hindered recognition of cognitive/behavioural mani-
festations (1). Over recent decades, an increasing
number of publications have focused on these
aspects, with emergence of diagnostic criteria for
frontotemporal dementia (FTD) (2) and mild cog-
nitive impairment (3), both of which can be present
in ALS patients. It is now known that 7%–41% of
ALS patients have FTD and 10%–70% have mild
cognitive/behavioural impairment, depending on the
series and diagnostic criteria used (4).
There are no epidemiological studies on the
prevalence and incidence of cognitive/behavioural
impairment in ALS patients in Spain, despite
reports advocating routine cognitive/behavioural
assessment in ALS hospital units (4). The reference
standard for this purpose is neuropsychological
examination, which is costly, time-consuming, and
not always applicable to this population. Because of
these limitations, several tools have been
designed to estimate the cognitive/behavioural state
of these patients. One such instrument is the ALS
Cognitive Behavioural Screen (ALS-CBS) (5).
The aims of this study were to validate the
Spanish version of the ALS-CBS and determine the
percentage of ALS patients presenting
cognitive/behavioural impairment in our setting.
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The study included consecutive new patients of any
age and either gender attending the Motor Neuron
Disease Unit of our hospital. Patients who met the
revised El Escorial diagnostic criteria (6) for definite
or probable ALS and were accompanied by a valid
caregiver in the opinion of the attending physician
were considered candidates. Patients who could not
be evaluated because of their clinical condition or
sensory deficits were excluded. Patients gave
informed consent for participation.
The initial visit to investigate suspected motor
neuron disease included detailed clinical history
taking, neurological examination, laboratory ana-
lyses (thyroid function, cobalamin, folate, creatine
kinase, urate, ferritin, protein and lipid profiles,
syphilis serology) and genetic sequencing. In add-
ition, patients underwent assessment with the ALS
Functional Rating Scale-Revised (ALSFRS-R) (7)
and forced vital capacity (FVC) testing.
Electromyography study and lumbar puncture
were performed, and cranial/cervical magnetic res-
onance (MR) imaging and 18-FDG positron emis-
sion tomography (PET) of the brain were requested.
The neuroimaging results will be reported in
another, related paper.
Patients who met the inclusion criteria and had
no criteria for exclusion were then assessed by two
neurologists with broad experience evaluating cog-
nitive/behavioural impairment (Dementia Unit).
The visit included history taking, neurological
examination, the Folstein MMSE test (8), and the
Spanish version of the ALS-CBS, which was always
administered after the neurological diagnosis.
Findings from complementary tests were also
evaluated. Clinical criteria were used to conclude
the diagnosis, which was based on the recent
consensus criteria for diagnosing cognitive/behav-
ioural impairment in ALS patients (4) and the
Neary criteria for FTD (2). Six diagnostic categories
were established:
 ALS with no cognitive/behavioural impairment
 ALS with mild cognitive impairment (ALSci)
 ALS with mild behavioural impairment (ALSbi)
 ALS with mild cognitive and behavioural
impairment (ALScibi)
 ALS with frontotemporal dementia (ALS-FTD)
 ALS with another type of dementia
Within 30 days after the neurological examin-
ation, patients were seen by a neuropsychologist
blinded to the neurologist’s findings. Patients were
tested with a neuropsychological battery created for
the study to classify them according to the Neary
criteria for FTD diagnoses (2) and the consensus
criteria for mild impairment diagnoses (4). To
establish mild cognitive impairment, the patient’s
performance had to be at or below the 5th percentile
compared to age- and education-matched norms on
at least two different cognitive tests, and could not
be related to the premorbid intellectual level, bulbar
dysfunction, motor weakness, or to neurological,
systemic, pharmacological, or severe psychiatric
comorbidities. Mild behavioural impairment was
diagnosed on the presence of two non-overlapping
behavioural abnormalities supported by at least two
sources from among a patient interview/observation,
caregiver report, or structured questionnaire/inter-
view, and after having ruled out a psychiatric
condition, psychological reaction, premorbid per-
sonality disorder, or a pseudobulbar affect. In all
patients studied, the assessment took into account
normative values according to age and educational
level for the Spanish population.
The battery included several tests. Executive
function was investigated with the Category Fluency
(animals) and Letter Fluency (using P, M, and R)
tasks (9,10) to assess fluency; the Stroop Color and
Word Test (11) and Trail Making Test (12) to
evaluate inhibition and mental flexibility, the
Wisconsin Card Sorting Test (13) and Tower of
London Test (14) to study abstraction and problem
solving, the Similarities Test (15) to check verbal
reasoning, and the WMS-III Digits subtest (16) to
evaluate selective attention and working memory.
Language assessment used the Boston Naming
Test (17), and semantic knowledge was evaluated
with the Complex Ideation/Commands Test (9) and
Pyramids and Palm Trees Test (18).
Psychomotor speed was assessed with the WAIS-
III Symbol Search (15), memory and verbal learning
with the Rey Auditory Verbal Learning Test (19),
visual memory with the WMS-III Faces and Family
Pictures subtests (20), and visuospatial ability with
the Judgement of Line Orientation Test (21,22).
Premorbid IQ was estimated with the WAIS-III
Vocabulary subtest (15).
Psychopathological and neuropsychiatric symp-
toms were evaluated with the Beck Depression
Inventory (23), Neuropsychiatric Inventory
(24,25), Apathy Scale (26), and Frontal
Behavioural Inventory (27).
The ALS-CBS instrument has two parts, a
cognitive section and a behavioural questionnaire.
The cognitive section comprises four subscales
yielding a total score of 20, with lower scores
indicating greater impairment. Responses are pro-
vided verbally or in writing. Scoring is based on a
combination of the scores for each item and the
number of errors made, in keeping with the rules of
the original version. The behavioural questionnaire
includes 15 caregiver-rated items that assess changes
noted in the patient since disease onset. Items are
scored from 0 (a large change) to 3 (no change) and
the total ranges from 0 to 45.
A fully bilingual professional translator was
engaged to translate the English text into Spanish.
The letter F, used in the English version as the guide
for evaluating verbal fluency, was preserved in the











































Spanish version, as the percentage of words starting
with F is similar in the two languages. Thus, the
same cut-off could be used in the Spanish version as
in the original. A second professional translator
performed a back translation into English of the
Spanish text to confirm that the original and the
back translation were equivalent.
Data collection
Independent variables collected from patients and
caregivers were recorded in an ad hoc encrypted
database, created using the Bento program for iPad.
The information included imaging findings, the
diagnostic categories ascribed to patients by clin-
icians, the neuropsychologist’s evaluation, and the
ALS-CBS scores.
Statistics
Statistical analyses were carried out with SPSS,
version 15.0. The mean, range, and standard
deviation were calculated for descriptive variables,
MMSE test scores, and ALS-CBS scores. The
percentages of patients in each diagnostic category
classified according to the two assessments (neur-
ologist/neuropsychologist) were also calculated.
Between-group comparisons were performed using
a Student’s t-test for means, a 2 test for percent-
ages, and a Fisher’s F test for standard deviations.
A p value of 50.05 was considered significant.
Variables showing significant differences were
included in a logistic regression model.
The sensitivity, specificity, and positive and
negative predictive values of the Spanish ALS-CBS
were calculated relative to the reference standard
neuropsychological evaluation. Optimal cut-off
values for diagnosing ALS-related cognitive/behav-
ioural impairment and FTD were also established.
Results
Between 1 October 2012 and 1 October 2013, 78
patients who met the inclusion criteria and had no
criteria for exclusion were enrolled. Twenty-six
patients were unable to complete the neuropsycho-
logical study. One patient (ALSci) was excluded due
to depression (BDI score was 23, and the investiga-
tor judged that the clinical-neurological evaluation
would be affected) and another due to previous head
trauma. Of the 50 patients completing the study,
64% were males and mean age was 62.3 years (range
36–86; 32%560 years, 32%470 years). Almost half
(48%) had less than eight years of schooling. A
family history of dementia was recorded in eight
patients (seven Alzheimer’s disease), motor neuron
disease in two, and Parkinson’s disease in four.
Mean disease duration since symptoms onset was 18
months (range 3–68; 40%512 months, 16%424
months) (Table I). In total, 76% of patients had
spinal-onset ALS and 22% bulbar onset (dysarthria
in 90%). At the time of the study, 58% of patients
had bulbar symptoms.
Based on the neuropsychological assessment,
12% of patients had FTD. Some degree of
frontotemporal cognitive/behavioural impairment
(including dementia) was seen in 64% of patients.
Also based on the neuropsychological assessment,
cognitive impairment (ALSci + ALScibi + ALS-
FTD) was diagnosed in 58% and behavioural
disorder (ALSbi + ALS-FTD) in 30% of patients.
The most commonly affected cognitive domains
were executive function (60%), verbal or visual
memory (35%), and language (12%). When verbal
fluency (31%) was removed from executive func-
tion, this domain was affected in 29% of cases and
language in 15%. The most common psychobeha-
vioural symptoms were irritability (40%), impa-
tience (30%), depression (24%), apathy (12%), and
disinhibition (10%). Emotional lability was
observed in 58% of cases.
Mean MMSE score was 27 points (range
16–30). Mean ALS-CBS scores were 12 points
(range 1–19) for the cognitive section and 34 points
(0–45) for the behavioural. The percentages of
patients ascribed to each diagnostic category based
on the clinicians’ and neuropsychologist’s evaluation,
respectively, were as follows: normal 30%, 36%;
ALSci 34%, 34%; ALSbi 8%, 6%; ALScibi 16%,














560 6 (37.5) 10 (62.5) 16 (32) None or58 7 (29.2) 17 (70.8) 24 (48)
60–69 8 (44.4) 10 (55.6) 18 (36) 8–14 7 (46.7) 8 (53.3) 15 (30)
70 4 (25) 12 (75) 16 (32) 15 4 (36.4) 7 (63.6) 11 (22)

















512 9 (45) 11 (55) 20 (40) 512 3 (15) 17 (85) 20 (40)
12–23 8 (36.4) 14 (63.6) 22 (44) 12–23 8 (36.4) 14 (63.6) 22 (44)
24 1 (12.5) 7 (87.5) 8 (16) 24 1 (12.5) 7 (87.5) 8 (16)
Total 18 (36) 32 (64) 50 (100) Total 11 (22) 38 (76) 50 (100)
ALS: amyotrophic lateral sclerosis.











































12%; and ALS-FTD 12%, 12%; two patients in this
last category were diagnosed with ALS-FTD plus
Parkinson’s disease. Overall agreement between the
two evaluations was 90%, and agreement for
ALS-FTD was 100%. No significant differences
were found between those who underwent the
complete study and those who did not (Table II).
The clinical-neurological evaluation results and
ALS-CBS scores were compared with the reference
standard (neuropsychological evaluation) to validate
the Spanish version of the ALS-CBS. To detect
significant differences in the variables studied, the
sample was divided, and two separate analyses were
performed: the first included ALS patients with
normal cognitive/behavioural status versus those
with any impairment (ALSci, ALSbi, ALScibi,
ALS-FTD) and the second included patients with-
out ALS-FTD (normal, ALSci, ALSbi, ALScibi)
versus ALS-FTD patients. The sensitivity, specifi-
city, positive predictive value, and negative predict-
ive value of the ALS-CBS in the two scenarios are
shown in Table III with the respective cut-offs.
In the first scenario (ALS normal vs. ALS any
impairment), the following variables showed signifi-
cant differences: mean age (56.7 vs. 65.4 years,
p50.014), low educational level (58 years school-
ing, 16.7% vs. 65.6%; p50.001), percentage with
depression (5.6% vs. 34.4%, p50.036), ALS-CBS
cognitive score 15 (33.3% vs. 81.8%, p50.0001),
ALS-CBS behavioural score36 (22.2% vs. 59.4%,
p50.018), mean ALS-CBS cognitive and behav-
ioural scores (16.6 vs. 9.66, p50.0001 and 40.11 vs.
30.41, p50.001, respectively), and presence of a
palmomental reflex (55.6% vs. 84.4%, p50.03).
There were no significant differences in gender,
disease duration, or type of onset (spinal vs. bulbar).
Differences in the type of onset were found
between patients with cognitive impairment: 34.5%
of patients with cognitive involvement (ALSci,
ALScibi, FTD) had a bulbar onset, whereas only
4.8% of patients without cognitive deterioration
debuted in this manner (p50.016).
On logistic regression analysis, independent
variables related to a risk of developing cognitive
impairment were age (Exp(B): 1.079; CI
1.031–1.130) and ALS-CBS cognitive score
(Exp(B): 0.731; CI 0.603–0.886).
In the second scenario (ALS with FTD vs. ALS
without FTD), significant differences were seen for
bulbar onset (66.7% vs. 15.9%, p50.017), devel-
opment of bulbar symptoms (100% vs. 52.3%,
p50.033), ALS-CBS cognitive score 8 (83.3% vs.
25.0%, p50.01), ALS-CBS behavioural score 35
(83.3% vs. 34.1%, p50.032), and mean ALS-CBS
cognitive and behavioural scores (5.3 vs. 12.8,
p50.0001 and 24.17 vs. 35.2, p50.027, respect-
ively). We found no significant differences in gender,
Table III. Neurological diagnoses and neuropsychological diagnoses. Sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV) and area under the curve (AUC) of the ALS-CBS validated in our ALS population.
Normal, % ALSci, % ALSbi, % ALScibi, % ALS-FTD, %
Neurological diag. 30 34 8 16 12
Neuropsychological diag. 36 34 6 12 12
Sensitivity, % Specificity, % PPV, % NPV, % Kappa
Neurologist vs. Neuropsychologist, to classify Normal vs. CI 100 83.3 91.4 100 0.85
Sensitivity, % Specificity, % PPV, % NPV, % AUC, %
ALS-CBScog, cut-off: 8 No FTD vs. FTD 83.3 75 31.3 97.1 87.3
ALS-CBScog, cut-off: 15 Normal vs. CI 86.2 62 75.8 76.5 84.7
ALS-CBSbv, cut-off: 35 No FTD vs. FTD 83.3 69 25 96.7 80.9
ALS-CBSbv, cut-off: 36 Normal vs. CI 93.3 74.3 61 96.3 83.3
ALSci: amyotrophic lateral sclerosis with cognitive impairment; ALSbi: amyotrophic lateral sclerosis with behavioural impairment;
ALScibi: amyotrophic lateral sclerosis with cognitive and behavioural impairment; ALS-FTD: amyotrophic lateral sclerosis with
frontotemporal dementia; diag: diagnoses; CI: cognitive impairment; ALS-CBScog: ALS-CBS cognitive subscale; FTD: frontotemporal
dementia; ALS-CBSbv: ALS-CBS behavioural subscale.
Table II. Demographic differences between patients who com-
pleted both the neurological and neuropsychological evaluations








Men 64.0% 57.1% 0.360
Women 36.0% 42.9%




Lower education (58 years) 48% 35.7% 0.209
Higher education 52% 64.3%
Normal 36.0% 28.6% 0.341
Some cognitive impairment 64.0% 71.4%
No dementia 88% 96.4% 0.206
Dementia 12% 3.6%
Mean ALS-CBS 12 12.11 0.909
Mean ALSFRS-R score 29.16 26.7 0.272
Mean FVC 79% 69% 0.125
Bulbar onset 22% 17.9% 0.457
Bulbar signs at the time
of cognitive assessment
58% 53.6% 0.443
ALS: amyotrophic lateral sclerosis; ALS-CBS: amyotrophic
lateral sclerosis cognitive behavioural screen; ALSFRS-R:
revised amyotrophic lateral sclerosis functional rating scale;
FCV: forced vital capacity.











































age, educational level, presence of depression or
palmomental reflex, or disease duration.
On logistic regression analysis, the ALS-CBS
cognitive score was independently related to FTD
(Exp(B): 0.793; CI 0.707–0.891). In both logistic
regression analyses, we used the diagnoses based on
the neuropsychological assessment.
There were no significant differences in the
mean FVC values or ALSFRS-R scores between
the groups in either of the two scenarios analysed.
Discussion
Woolley et al. developed the ALS-CBS as a quick
screening instrument to detect cognitive/behavioural
impairment in ALS. In the present study, a version
of this instrument in the Spanish language was
developed and validated on a sample of ALS
patients in our setting. The Spanish ALS-CBS
proved useful for screening in this population. The
sensitivity and specificity values were similar to
those of the original instrument (5), although
optimal cut-off scores for screening were lower,
probably because of the relatively low educational
level of our population. As occurred with the
original instrument, the performance of the behav-
ioural section was somewhat lower than the cogni-
tive section. We obtained excellent negative
predictive values that enabled acceptably reliable
estimation of which patients did not present impair-
ment or dementia. The lower positive predictive
values imply that a higher percentage of patients will
require extensive neuropsychological evaluation.
The utility of the clinical-neurological evaluation
(including ALS-CBS) approached that of the refer-
ence neuropsychological assessment for determining
whether patients had cognitive/behavioural impair-
ment. In regular practice there would be a consid-
erable time saving for the system and the patient if
only the clinical-neurological evaluation were per-
formed in the initial assessment. Based on this
simplified screening, patients with cognitive impair-
ment could then be reliably referred to a specialist
for further evaluation. Neuropsychological assess-
ment has a major impact on the patient, as is
evidenced by the large percentage of our initial
cohort who could not complete or refused to
complete the evaluation (35%).
The percentages of patients placed in the various
cognitive impairment diagnostic groups were similar
to reported values (1,28,29). The high percentage
with cognitive impairment and the rate with which
this condition is underdiagnosed were similar to
values reported in an epidemiological study per-
formed in Barcelona (80%) (30). The clinical-
neurological evaluation coincided with the reference
standard evaluation in most cases of cognitive
impairment, with full concordance for FTD. In
keeping with reported findings, the most highly
affected cognitive domain in our patients was
executive function (1,28,29), although a recent
study has cited language as the most profoundly
affected domain (31). To further investigate this
aspect, we reanalysed the affected cognitive domains
excluding verbal fluency from executive function;
nonetheless, executive function persisted as the
domain showing the greatest changes. One potential
explanation for the differences between studies of
this type may be the design of the neuropsycho-
logical batteries used. A greater presence of tests
examining a specific domain may increase the
sensitivity for detecting changes in that area.
As has been described (1,32), a higher percent-
age of ALS patients with bulbar onset had FTD
than those with spinal onset. This difference was not
found in the analysis of patients with no impairment
versus any impairment, but it was when patients
with pure behavioural disorder were excluded.
As this is not a population based study, we are
unable to provide definite conclusions regarding the
contribution of traditional risk factors such as age
and educational level on the risk of experiencing
FTD or mild impairment. Nonetheless, our findings
concur with those of Woolley, in that educational
level is not a determinant of risk in these patients; it
is a risk factor for Alzheimer’s disease and for
dementia in general (30,33), but not for FTD (34).
The initial significance of this factor in our analysis
may be related to the role of age as an independent
variable associated with cognitive impairment. In
our specific population, the older the age, the
greater the likelihood that patients would have a
lower educational level. Age seemed to be an
independent risk factor for the diagnosis of impair-
ment in general, but not specifically for FTD,
perhaps because of the low number of FTD patients
included in the analysis. An increase in the incidence
of FTD has been described with ageing, up to the
age of 70 years (34). In our series, 65% of patients
were younger than 70 years of age, and this may be
why we found a certain age-associated risk for
presenting any type of cognitive/behavioural
impairment.
The role of depression as a confounding factor
remains to be resolved (1,5). Depression could be a
psychobehavioural symptom associated with cogni-
tive impairment in ALS or an adaptive state that
interferes with the patients’ cognitive performance.
In our series, 24% of patients presented depressive
symptoms on evaluation, mild in 90%. Nonetheless,
the data do not suggest overdiagnosis of FTD due to
depression, since the percentage with this factor was
similar between those with and without FTD.
Furthermore, although depression was more
common in patients with any impairment than in
those without, it was not an independent risk factor
for impairment on multivariate analysis (p¼ 0.1).
An elevated rate of depression has been reported in
caregivers of ALS patients, and this has generated











































interest in studying the impact of the disease on
quality of life of the patients’ family members
(35,36). Better knowledge of the patients’ cognitive
and behavioural situation would favour optimal
management by physicians and improvements for
caregivers, who could experience reductions in their
care burden.
Another issue that must be addressed is whether
cognitive impairment or behavioural disorder are
independently related to a poor prognosis in these
patients or are actually self-fulfilling prophesies,
being linked with the use of less intensive therapy. It
could be in the patient’s interest to establish clear
lines of action regarding therapy. For example,
future decisions could be protocoled early, when
incipient impairment is first detected. It could also
be helpful to create instruments to determine the
capacity of a patient with impairment or FTD to
take decisions. According to some authors, behav-
ioural disorder (37) and executive function changes
(38,39) are associated with a poorer prognosis,
whereas others have not found these relationships
(40). The future follow-up of our patients will
enable us to discuss this issue.
In contrast to Woolley’s results (5), we found no
correlation between ALS-CBS scores and FVC
values or ALSFRS scores (p40.05). Nor did we
detect significant differences in the mean FVC or
ALSFRS between patients with and without any
impairment, or between those with and without
dementia. Hence, we concur with Woolley’s sugges-
tion that this association would result from the
influence of the bulbar-onset form for both factors.
It seems equally reasonable that there would be no
relationship with the functional status (ALSFRS),
since FTD and ALS can be onset forms or appear
sequentially in an interchangeable manner.
Conclusions
In conclusion, the Spanish version of the ALS-CBS
test is a useful instrument for screening cognitive/
behavioural impairment in ALS patients in our
setting. We found a high rate of impairment in the
cohort evaluated, especially in those with a bulbar
onset; hence, it seems advisable to include cognitive
screening in the initial evaluation of these patients.
This practice could result in better patient manage-
ment, benefits for caregivers, and improved deci-
sion-making.
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